Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
11 oct. 2023 08h07 HE
|
Autolus Therapeutics plc
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
11 oct. 2023 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
05 sept. 2023 07h00 HE
|
Autolus Therapeutics plc
Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...
Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
03 août 2023 07h00 HE
|
Autolus Therapeutics plc
Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
19 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON,...
Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023
18 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
06 juil. 2023 07h00 HE
|
Autolus Therapeutics plc
Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...
Autolus Therapeutics announces publication in Cancer Immunology Research
27 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director
20 juin 2023 07h00 HE
|
Autolus Therapeutics plc
LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
16 juin 2023 07h00 HE
|
Autolus Therapeutics plc
At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...